Упрощенная HTML-версия
146
208. Husain S. Aspirin improves endothelial dysfunction in atherosclerosis /
S. Husain, N.P. Andrews, D. Mulcahy et al. // Circulation. – 1998. – № 97. – Р.
716–720.
209. Jarvis B. Clopidogrel: a review of its use in the prevention of
atherothrombosis / B. Jarvis, K. Simpson // Drugs. – 2000. – Vol. 60 (2). – Р. 347-
377.
210. Jones L. Clinical effectiveness and cost-effectiveness of clopidogrel and
modified-release dipyridamole in the secondary prevention of occlusive vascular
events: a systematic review and economic evaluation / L. Jones, S. Griffin, S.
Palmer, et al. // Health Technol. Assess. – 2004. – Vol. 8 (38). – P. 196.
211. Kannel W.B. Prognosis after initial myocardial infarction: the
Framing Study / W.B. Kannel, P. Sorlie, P.M. McNamara // Am. J. Cardiol. –
1979. – Vol. 44. – Р. 53-59.
212. Klinkhardt U. Clopidogrel but not aspirin reduces P-selectin expression
and formation of platelet-leukocyte aggregates in patients with atherosclerotic
vascular disease / U. Klinkhardt, R. Bauersachs, J. Adams et al. // Clin. Pharmacol.
Ther. – 2003. – Vol. 73 (3). – Р. 232-241.
213. Koenig W. Haemostatic risk factors for cardiovascular disease / W.
Koenig // Eur. Heart J. – 1998. – №19. – Р. С39-С43.
214. Kroll M.H. Biochemical mechanisms of platelet activation / M.H. Kroll,
A.I. Schafer // Blood. – 1989. – Vol. 74. – P. 1181-1195.
215. Kuliczkowski W. Aspirin resistance in ischaemic heart disease / W.
Kuliczkowski, B. Halawa, B. Korolko et al. // Kardiol Pol. – 2005. – Vol. 62 (1). –
Р. 14-25.
216. Lakatta E.G. Cardiovascular ageing in health sets the stage for
cardiovascular disease / E.G. Lakatta // Heart Lung Circ. – 2002. – Vol. 11 (2). – Р.
76-91.
217. Levi F. Trends in mortality from cardiovascular and cerebrovascular
disease in Europe and areas of the world / F. Levi, F. Lucchini, E. Negri et al. //
Heart. – 2002. – № 88 (2). – Р. 119-124.
218. Libby P. Pathophysiology of coronary artery disease / P. Libby, P.
Theroux // Circulation. – 2005. – Vol. 111 (25). – Р. 3481-3488.